A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
University of Miami
Seagen Inc.
Tizona Therapeutics, Inc
IDEAYA Biosciences
Eli Lilly and Company
Seagen Inc.
Sairopa B.V.
Tempest Therapeutics
Washington University School of Medicine
Carisma Therapeutics Inc
EDDC (Experimental Drug Development Centre), A*STAR Research Entities
Pliant Therapeutics, Inc.
Corvus Pharmaceuticals, Inc.
Xencor, Inc.
Incyte Corporation
HonorHealth Research Institute
Eisai Inc.